All In Biotech

Drug Trial Radar · NCT02090283

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

An Open Label Extension, Multi-Center, Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa

Last checked: Nov 19, 2026Latest source record: Nov 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

42

Actual

Start

Mar 26, 2014

Primary completion

Sep 14, 2018

Study completion Sep 14, 2018

Sponsor

Lead sponsor
Scioderm, Inc.Industry
Sponsor type
Industry
Collaborators
Amicus Therapeutics; Food and Drug Administration (FDA)
First posted
Mar 18, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the continued safety of topical use of SD-101 cream (6%) in participants with Epidermolysis Bullosa (EB). Funding Source: FDA Office of Orphan Products Development

Conditions

  • Epidermolysis Bullosa

Interventions

  • SD-101 dermal cream (6%)Drug

    SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number Of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From baseline to 30 days after last application of study drug (up to a maximum of 54 months)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Palo Alto, California

  • Site not named

    Chicago, Illinois

  • Site not named

    St Louis, Missouri

  • Site not named

    Hackensack, New Jersey

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    San Antonio, Texas

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.